Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Merck Still a Strong Buy?

TheMotleyFool

0 0

Merck (NYSE: MRK) has long been the apple of investor's eyes, both for its excellent financials and solid dividend payouts. The company enjoyed monumental sales growth in Q3, with aggregate profits reaching $12.4 billion and an overall revenue surge of 15%.

Surpassing analyst's expectations, Merck elevated its full-year earnings outlook to the $46.5 billion to $47 billion range, which was a notable rise from the anticipated profits of $45.2 billion to $46.2 billion. While Merck is known for a variety of pharmaceutical products, there was one drug in particular that accounted for the better part of its profits and forecast boost in Q3: its blockbuster anti-cancer drug Keytruda.

Image Source: Getty Images

Source Fool.com

Like: 0

MRK

Share